Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095537 · ClinicalTrials.gov registry record · Phase 1
BMS-599626 in Patients With Advanced Solid Malignancies
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00095537 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants.
The verdict
NCT00095537, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21 days with a 7 day rest period in patients with cancer who no longer benefit from other commonly used treatments. The study will also test for other proteins that may be affected by BMS-599626; and the level of study drug in the blood will be studied.
Interventions
- DRUG panHer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095537
The ClinicalTrials.gov registry entry for NCT00095537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which panHer is the first listed.
NCT00095537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095537 about?
NCT00095537 is a clinical study titled "BMS-599626 in Patients With Advanced Solid Malignancies". The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21 days with a 7 day rest period in patients with cancer who no longer benefit from other commonly used treatments. Th...
What is the current status of trial NCT00095537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00095537?
The interventions under investigation include: panHer (DRUG).
Who is sponsoring clinical trial NCT00095537?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.